Sera Prognostics, Inc. (SERA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnin ...

Accessibility StatementSkip Navigation The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY, Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the findings of the Prematurity Risk Assessmen ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Sera Prognostics, Inc. reported a quarterly loss of $0.16 per share, which was better than the Zacks Consensus Estimate of a loss of $0.19, indicating an earnings surprise of +15.79% [1] Group 1: Earnings Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The quarterly revenue was $0.02 million, missing the Zacks Consensus Estimate by 75.39%, compared to $0.03 million in the same quarter last year [2] - The stock has lost approximately 61.7% since the beginning of the year, while the S&P 500 has gained 16.5% [3] Group 2: Future Outlook - The future performance of Sera Prognostics' stock will depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $0.1 million, and for the current fiscal year, it is -$0.73 on revenues of $0.12 million [7] Group 3: Industry Context - The Medical Services industry, to which Sera Prognostics belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, which may impact the stock's performance [8]

Sera Prognostics (NasdaqGM:SERA) Q3 2025 Earnings Call November 13, 2025 05:00 PM ET Speaker5Afternoon, and welcome to the Sera Prognostics conference call to review third-quarter fiscal year 2025 results. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would like to turn the call over to Jennifer Zebuda, Sera's Head of Investor Relations, for a few ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40606 SERA PROGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 26-1911522 | | --- | --- | | (State or other ...

Exhibit 99.1 SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS Salt Lake City – November 13, 2025 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025. Third Quarter and Recent Highlights: states in discussion. In addition, we are actively engaged with payers who are b ...

Core Insights - Sera Prognostics Inc. will report its third quarter fiscal year 2025 financial results on November 13, 2025, followed by a conference call to discuss operational highlights and financial results [1][2] Company Overview - Sera Prognostics is dedicated to improving maternal and neonatal health through innovative pregnancy biomarker information, aiming to reduce healthcare delivery costs [3] - The company has a robust pipeline of diagnostic tests focused on early prediction of preterm birth risk and other pregnancy complications [3] - The PreTRM® Test is a key product that provides individualized risk predictions for spontaneous preterm birth, allowing for proactive interventions [5] Industry Context - Preterm birth, defined as any birth before 37 weeks' gestation, is the leading cause of illness and death in newborns, with over 10% of infants born prematurely in the U.S. for the last six years [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4]

Core Viewpoint - Sera Prognostics Inc. has appointed Dr. Tiffany Inglis as Chief Medical Officer to enhance its leadership in women's health diagnostics, particularly focusing on improving maternal and neonatal health through innovative pregnancy biomarker testing [1][2][3]. Company Overview - Sera Prognostics is dedicated to improving the lives of women and babies through precision pregnancy care, aiming to provide early and pivotal pregnancy information to enhance maternal and neonatal health and reduce healthcare delivery costs [4]. Leadership Appointment - Dr. Tiffany Inglis brings extensive clinical leadership experience from Elevance Health and Carelon Health, where she focused on women's and children's health, improving access to quality care while achieving cost savings [2][3]. - Her clinical expertise and experience with major payer networks position her well to lead Sera's clinical operations during a critical phase, including the upcoming publication of the PRIME study and pilot programs with state Medicaid [3][4]. Product Focus - Sera's PreTRM® Test is a blood-based biomarker test that provides early, accurate, and individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies, allowing for informed clinical decisions [6][7]. - The test measures proteins in the blood that are highly predictive of preterm birth, enabling identification of at-risk women between 18 and 20 weeks of pregnancy [6][7]. Industry Context - Preterm birth, defined as any birth before 37 weeks' gestation, is a leading cause of illness and death in newborns, with over 10% of infants born prematurely in the U.S. for the last six years [5]. - The healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [5].

Core Insights - Sera Prognostics has experienced a noticeable cooling in its performance after a previous hot streak, leading to a reevaluation of its investment status from "Hold" [1] Company Overview - The article reflects on the author's investment journey, emphasizing the learning process involved in investing, particularly in healthcare stocks [1] Investment Perspective - The author shares insights from decades of investing experience and focused research on various stocks, with a recent emphasis on healthcare [1]